COMPANY
History
KHAV is a vaccine, therapeutics R&D and CRO company that contributes to human
and animal health through the development of next-generation vaccines.
-
- 2022
-
- SCL HealthCare
- CerntralBlo Inc.
- Signing MOU
-
- 2021
-
- Attracting capital investment by institutional investors (Intervest, BRIC, LOFTYROCK, SIMPAC, KG ZEROIN)
- License contract for ECLS mucosal adjuvant of EurCorVac-19 (COVID-19 Recombinant Protein Vaccine)
-
- 2020
-
- Certification of credit rating agencies
- Grant Agreement : Development of Recombinant Protein Antigen and Adjuvant Platform Technology for COVID-19 Preventive Vaccine (National Research Foundation of Korea)
- Grant Agreement : Development of SARS-CoV-2 recombinant vaccines as a nanogel formulationfor oral administration through sublingual routes (RIGHT FUND)
- Bionote Capital Investment Attraction
- Joint Technology Commercialization COVID-19 Vaccine Development Technology Agreement(BIONOTE Inc.)
-
- 2019
-
- Research service cooperation agreement for development of IB vaccine customized in Indonesia
-
- 2018
-
- Facility investment based on the establishment of a manufacturing plant
- Acquisition of medicine manufacturing license and factory registration
-
- 2017
-
- Certification of excellent technology evaluation companies
- Future Growth Engine Challenge Demo Day Excellence Award (Ministry of Science, ICT and Future Planning)
-
- 2016
-
- Grand Prize for Innovative Koreans & POWER KOREA R&D Division
- 2016 BRIDGE FESTIVAL Excellence Award
-
- 2015
-
- Establishment of KHAV Inc. laboratory
- Corporate affiliation laboratory recognition
-
- 2014
-
- Konkuk University Technology Holding Company Registration
- Establishment of KHAV Co.,Ltd